Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

Objective To elucidate the common and distinct clinical features of immune-mediated necrotising myopathy (IMNM), also known as necrotising autoimmune myopathy associated with autoantibodies against ...

In our cohort, 6 of 7 patients with isolated anti-Ku presented typical immune-mediated necrotizing myopathy (IMNM)-like pathological features with predominantly necrotic muscle fibre and CD68 + ...

Discover Cabaletta Bio's promising CAR T-cell therapy for autoimmune diseases! Durable efficacy, FDA support, and clinical potential make this attractive.

Christopher‐Stine L et al. A novel autoantibody recognizing 200‐kd and 100‐kd proteins is associated with an immune‐mediated necrotising myopathy. Arthritis & Rheumatism. 2010;62(9):2757-66. Watanabe ...

GlobalData’s report assesses how Immune globulin (human)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here. GlobalData tracks ...

The ALKIVIA study is a randomized, double-blind, placebo-controlled, multicenter, operationally seamless Phase 2/3 study of efgartigimod SC for the treatment of idiopathic inflammatory myopathies (IIM ...